Why is it so daunting for US biotech and pharma to launch drugs in Europe themselves?

by Anna Casse, Managing Partner and Saadia Basharat, Consultant, at Alacrita
Learn More

How best to Prioritize the IP Portfolio in Universities, Charities and Research Funding Bodies?

by Saadia Basharat, PhD, Consultant, Alacrita
Learn More

What’s the difference between biotech and pharma? 

What’s the difference between biotech and pharma? How are biotechnology drugs different from traditional pharmaceuticals, and how are biotech companies different to pharma companies?
Learn More

Brexit: What are the options for UK registered MAHs?

By Saadia Basharat, PhD, Consultant
Learn More

European Biotech - Gaining weight and learning patience

European biotech has always been at an investment disadvantage relative to US biotech and this is reflected by the continuing lead in the USA on all financial parameters. This is not a result of...
Learn More

Zytiga – practice-changing clinical news but is it a home run?

ASCO provided practice-changing news for prostate cancer patients – Zytiga (abiraterone) added to standard hormone therapy in newly diagnosed high risk metastatic patients reduces the chance of death...
Learn More

The Wisdom of Henri Termeer, 1946-2017

What Can We Learn? Henri Termeer, one of the founding fathers of biopharma, died last week leaving a superb legacy of achievement in the industry. Always a colourful figure, some of his most...
Learn More

Colin Miller, medical imaging consultant, presents poster at OARSI meeting

Medical imaging expert and Alacrita Partner, Colin G Miller PhD, presented his poster titled "Standardization of imaging reads for eligibility assessment of patients — Component of a risk mitigation...
Learn More

BIO-Europe 2017: Clinical trials in Early Stage Oncology Development

Recently, I was fortunate enough to moderate a provocative panel on clinical trials in early stage oncology development at the BIO-Europe Spring meeting in Barcelona (19-22 March, 2017)
Learn More

Healthcare Rationing or Simply Prioritization?

An interesting paper by Roland Turck (doi:10.1093/annonc/mdw548) puts oncology drug pricing into a certain perspective. For me, the most perceptive remark is that while oncology drugs represent only...
Learn More

EMA solution for the post-Brexit era

Here's an idea: designate the EMA's location in Canary Wharf as sovereign EU territory (just as if it were an embassy) and then it could remain in London yet still be located in the EU...
Learn More

Post EMA approval: how soon can products be sold?

Question: After EMA approval, are sales of a pharmaceutical allowed in EU5, before pricing is approved? What is the soonest a company can sell a pharmaceutical agent in Europe after approval?
Learn More
Previous
1 ... 2 3 4 5 6

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.